Testing effectiveness (Phase 2)Study completedNCT01738438What this trial is testingCabozantinib for Metastatic Triple Negative BrCaWho this might be right forBreast Cancer Dana-Farber Cancer Institute 35
Testing effectiveness (Phase 2)Study completedNCT03620643What this trial is testingCrizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursWho this might be right forLobular Breast CarcinomaGastric CancerTriple Negative Breast Cancer+1 more Royal Marsden NHS Foundation Trust 33
Not applicableUnknownNCT04582955What this trial is testingNeoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and ChemotherapyWho this might be right forTriple-negative Breast Cancer Tianjin Medical University Cancer Institute and Hospital 20
Early research (Phase 1)Ended earlyNCT04315233What this trial is testingRibociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsWho this might be right forMetastatic Breast CancerRecurrent Ovarian Carcinoma University of Utah 12
Early research (Phase 1)Study completedNCT04879849What this trial is testingTAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersWho this might be right forCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck Takeda 34
Testing effectiveness (Phase 2)Study completedNCT01889238What this trial is testingSafety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerWho this might be right forAdvanced, Androgen Receptor Positive Triple Negative Breast Cancer Pfizer 118
Large-scale testing (Phase 3)Study completedNCT04799249What this trial is testingTrilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)Who this might be right forTNBC - Triple-Negative Breast CancerBreast Cancer G1 Therapeutics, Inc. 194
Not applicableLooking for participantsNCT06692725What this trial is testingDe-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBCWho this might be right forTriple Negative Breast Cancer Peking University People's Hospital 380
Early research (Phase 1)Study completedNCT03654547What this trial is testingSafety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast CancerWho this might be right forAdvanced Solid TumorsTriple Negative Breast Cancer TransThera Sciences (Nanjing), Inc. 48
Large-scale testing (Phase 3)Active Not RecruitingNCT05382299What this trial is testingStudy of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerWho this might be right forTriple Negative Breast CancerPD-L1 Negative Gilead Sciences 623
Testing effectiveness (Phase 2)Study completedNCT02593175What this trial is testingWomen's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCWho this might be right forStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7+8 more M.D. Anderson Cancer Center 43
Not applicableLooking for participantsNCT07546695What this trial is testingRole of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC StudyWho this might be right forBreast Cancer University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)UnknownNCT05088057What this trial is testingNeoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast CancerWho this might be right forTriple Negative Breast Cancer (TNBC) Aiping Shi 30
Testing effectiveness (Phase 2)Looking for participantsNCT06134375What this trial is testingTetrathiomolybdate (TM) Plus CapecitabineWho this might be right forTriple Negative Breast CancerResidual Disease Dartmouth-Hitchcock Medical Center 204
Early research (Phase 1)Study completedNCT00707707What this trial is testingPhase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerWho this might be right forBreast CancerTriple Negative Breast CancerMetastatic Breast Cancer AstraZeneca 19
Not applicableLooking for participantsNCT06349512What this trial is testing68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)Who this might be right forTriple Negative Breast Cancer Institut Curie 60
Early research (Phase 1)Study completedNCT02482311What this trial is testingSafety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursWho this might be right forOvarian Cancer, TNBC, SCLC, Other Solid Tumours AstraZeneca 92
Not applicableLooking for participantsNCT06991790What this trial is testingSacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker ExplorationWho this might be right forTNBC Peking University Cancer Hospital & Institute 51
Large-scale testing (Phase 3)UnknownNCT04907344What this trial is testingStudy of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Who this might be right forTriple Negative Breast Cancer Tianjin Medical University Cancer Institute and Hospital 420
Testing effectiveness (Phase 2)Study completedNCT01421472What this trial is testingA Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerWho this might be right forER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients Merrimack Pharmaceuticals 196